Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for high-risk neuroblastoma

Background Treatment for children with high-risk neuroblastoma relies on conventional chemotherapy and anti-GD2 immunotherapy. However, 5-year survival is only 50%, with high rates of late effects. Targeted therapy combinations are a major priority for these patients. The BCL2 inhibitor venetoclax, in combination with cyclophosphamide/topotecan, has clinical activity in relapsed and refractory neuroblastoma. We sought more effective and safer venetoclax combinations through systematic preclinical testing. Methods Synergistic combinations were identified by high-throughput screening using patient-derived xenograft (PDX) models and confirmed in vivo. The leading combination (venetoclax-alisertib) was compared to combination chemotherapy in a clinical trial-like study using 22 PDX models, in scheduling experiments designed to reduce short-term toxicity, and in combination with anti-GD2 immunotherapy. BCL2 and Bim-BCL2 complex protein levels were assessed as predictors of sensitivity. Results In vitro synergy with venetoclax was observed for standard-of-care chemotherapies and targeted agents, including DNA topoisomerase, microtubule, HDAC and Aurora kinase A (AURKA) inhibitors. Venetoclax-alisertib was particularly effective in vivo. In an n = 1 study, venetoclax-alisertib induced objective response in all models. Activity was most striking in models of MYCN -amplified disease ( n = 12), doubling median survival time compared to cyclophosphamide/topotecan, and outperforming venetoclax-cyclophosphamide-topotecan. Efficacy was maintained with discontinuous schedules, minimizing hematological toxicity without substantially compromising activity. Venetoclax-alisertib was strikingly effective with anti-GD2 immunotherapy, allowing long-term survival of PDX-engrafted animals. BCL2 expression and BCL2-Bim complex levels were of limited value for predicting response. Conclusions Our findings support advancement of BCL2-AURKA inhibition to clinical trial for high-risk neuroblastoma with or without anti-GD2 immunotherapy, particularly in patients with MYCN -amplified disease.

Authors

Institutions

Publication Details

Journal
Journal of Experimental & Clinical Cancer Research
Published
2026-11-18
DOI
https://doi.org/10.1186/s13046-026-03875-4
Primary Topic
Neuroblastoma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for high-risk neuroblastoma

Angela Lin, Alvin Kamili, Murray D. Norris, Roxanne Cadiz et al.
Journal of Experimental & Clinical Cancer Research
Neuroblastoma Research and Treatments
article

Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for high-risk neuroblastoma

Angela Lin, Alvin Kamili, Murray D. Norris, Roxanne Cadiz, Toby N. Trahair, Caroline J. Atkinson, M. Emmy M. Dolman, Marie Wong, Chelsea Mayoh, Andrew J. Gifford, Michelle Haber, Lujing Cui, Madeleine S. Wheatley, Jamie I. Fletcher, Greg M. Arndt, Jayne E. Murray, Timothy W. Failes, Christina H.T. Bui, Brandon A. Hearn, Lewis Crowley, Sadia Qureshi, Isabella Temelkoska, Leith-Justin Elhassadi, Joan Solomon
article en

Abstract

Background Treatment for children with high-risk neuroblastoma relies on conventional chemotherapy and anti-GD2 immunotherapy. However, 5-year survival is only 50%, with high rates of late effects. Targeted therapy combinations are a major priority for these patients. The BCL2 inhibitor venetoclax, in combination with cyclophosphamide/topotecan, has clinical activity in relapsed and refractory neuroblastoma. We sought more effective and safer venetoclax combinations through systematic preclinical testing. Methods Synergistic combinations were identified by high-throughput screening using patient-derived xenograft (PDX) models and confirmed in vivo. The leading combination (venetoclax-alisertib) was compared to combination chemotherapy in a clinical trial-like study using 22 PDX models, in scheduling experiments designed to reduce short-term toxicity, and in combination with anti-GD2 immunotherapy. BCL2 and Bim-BCL2 complex protein levels were assessed as predictors of sensitivity. Results In vitro synergy with venetoclax was observed for standard-of-care chemotherapies and targeted agents, including DNA topoisomerase, microtubule, HDAC and Aurora kinase A (AURKA) inhibitors. Venetoclax-alisertib was particularly effective in vivo. In an n = 1 study, venetoclax-alisertib induced objective response in all models. Activity was most striking in models of MYCN -amplified disease ( n = 12), doubling median survival time compared to cyclophosphamide/topotecan, and outperforming venetoclax-cyclophosphamide-topotecan. Efficacy was maintained with discontinuous schedules, minimizing hematological toxicity without substantially compromising activity. Venetoclax-alisertib was strikingly effective with anti-GD2 immunotherapy, allowing long-term survival of PDX-engrafted animals. BCL2 expression and BCL2-Bim complex levels were of limited value for predicting response. Conclusions Our findings support advancement of BCL2-AURKA inhibition to clinical trial for high-risk neuroblastoma with or without anti-GD2 immunotherapy, particularly in patients with MYCN -amplified disease.

Journal of Experimental & Clinical Cancer Research
UNSW Sydney (AU), Prince of Wales Hospital (AU), Children's Cancer Institute Australia (AU), Princess Máxima Center (NL), NSW Health Pathology (AU)
University of New South Wales, National Health and Medical Research Council
Good health and well-being
Neuroblastoma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon